Dranitsaris et al developed a score for predicting the risk of hand-foot skin reaction (HFSR) in a cancer patient treated with sorafenib. The authors are from Caduceaus Information Systems in Toronto, London Regional Cancer Program, Bayer HealthCare Pharmaceuticals and Memorial Sloan-Kettering Cancer Center
Patient selection: cancer treated with sorafenib
Outcome: hand-foot skin reaction >= Grade 2
Parameters:
(1) gender
(2) ECOG performance status
(3) lung metastases at baseline
(4) liver metastases at baseline
(5) number of organs involved
(6) baseline WBC count
(7) week of therapy
|
Parameter |
Finding |
Points |
|
gender |
Male |
0 |
|
|
Female |
6 |
|
ECOG performance |
0 |
0 |
|
|
1 or greater |
-7 |
|
lung mets at baseline |
No |
0 |
|
|
Yes |
-7 |
|
liver mets at baseline |
No |
0 |
|
|
Yes |
6 |
|
number of organs involved |
1 |
0 |
|
|
>= 2 |
9 |
|
baseline WBC count |
<= 5,500 per µL |
0 |
|
|
> 5,500 per µL |
5 |
|
week of therapy |
week 1 |
4 |
|
|
week 2 |
7 |
|
|
week 3 |
10 |
|
|
week 4 |
11 |
|
|
week 5 |
12 |
|
|
week 6 |
11 |
|
|
week 7 |
10 |
|
|
week 8 |
8 |
total score =
= 20 + SUM(points for all 7 parameters)
Interpretation:
• minimum score: 6
• maximum score: 58
• The higher the score the greater the risk for HFSR.
• A score > 40 was considered “at risk”.
|
Score |
Risk (Observed) |
|
<= 20 |
1.4% |
|
21 to 30 |
3.7% |
|
31 to 40 |
8.3% |
|
41 to 50 |
15% |
|
> 50 |
24% |
Specialty: Hematology Oncology, Dermatology
